Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969

Global prevalence of dementia: a Delphi consensus study

Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336

Defining the clinical course of multiple sclerosis

LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863

Practice parameter: Management of dementia (an evidence-based review) [RETIRED]

Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,708

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952

Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET

Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid

Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401

CSF biomarker variability in the Alzheimer's Association quality control program

Mattsson, N., Andréasson, U., Persson, S., Carrillo, M. C., Collins, S. J., Chalbot, S., Cutler, N. E., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 389

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375

Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258

Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine

Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Deerlin, V. M. V., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 278

Amyloid‐β efflux from the central nervous system into the plasma

Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254

Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study

Sharma, R. A., Varga, A. W., Bubu, O. M., Pirraglia, E., Kam, K., Parekh, A., Wohlleber, M. E., Miller, M. D., Andrade, A. G., Lewis, C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0704oc · Cited by 259

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease

Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236

Influence of comorbidities in idiopathic normal pressure hydrocephalus — research and clinical care. A report of the ISHCSF task force on comorbidities in INPH

Malm, J., Graff‐Radford, N. R., Ishikawa, M., Kristensen, B. W., Leinonen, V., Mori, E., Owler, B., Tullberg, M., Williams, M. A., & Relkin, N. R. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-22 · Cited by 235

Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial

Kim, H., Seo, S. W., Chang, J. W., Lee, J. I., Kim, C. H., Chin, J., Choi, S. J., Kwon, H., Yun, H. J., Lee, J. M., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.007 · Cited by 228

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Molinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 205

Reporting standards for studies of diagnostic test accuracy in dementia

Noel-Storr, A. H., McCleery, J. M., Richard, E., Ritchie, C. W., Flicker, L. A., Cullum, S. J., Davis, D. H. J., Quinn, T. J., Hyde, C., Rutjes, A. W., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000621 · Cited by 196

Designing the next-generation clinical care pathway for Alzheimer’s disease

Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191

Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

Lewczuk, P., Lelental, N., Spitzer, P., Maler, J. M., & Kornhuber, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140771 · Cited by 192

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 162

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations

Cosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 161

Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction

Evered, L. A., SILBERT, B. S., Scott, D. A., Ames, D. J., Maruff, P. T., & Blennow, K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000953 · Cited by 153

Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta

Arber, C., Toombs, J., Lovejoy, C., Ryan, N. S., Paterson, R. W., Willumsen, N., Gkanatsiou, E., Portelius, E., Blennow, K., Heslegrave, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0410-8 · Cited by 148

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.019 · Cited by 153

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147

Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 153

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 148

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136

Challenges of multimorbidity of the aging brain: a critical update

Jellinger, K. A., & Attems, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1288-x · Cited by 154

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 139

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 137

Biobanking of CSF: International standardization to optimize biomarker development

Teunissen, C. E., Tumani, H., Engelborghs, S., & Mollenhauer, B. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.12.024 · Cited by 137

Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus

Graff‐Radford, N. R. (2014) · Neurology · doi:10.1212/wnl.0000000000000916 · Cited by 125

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123

Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease

Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 119

Body fluid biomarkers for multiple sclerosis—the long road to clinical application

Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106

Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders

Miller, E. D., Morel, A., Saso, L., & Saluk, J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666141209160556 · Cited by 105

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease

Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109

Sleep oscillation-specific associations with Alzheimer’s disease CSF biomarkers: novel roles for sleep spindles and tau

Kam, K., Parekh, A., Sharma, R. A., Andrade, A. G., Lewin, M. P., Castillo, B., Bubu, O. M., Chua, N. J., Miller, M. D., Mullins, A. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0309-5 · Cited by 111

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS

Oeckl, P., Jardel, C., Salachas, F., Lamari, F., Andersen, P. M., Bowser, R. P., de Carvalho, M. A., Costa, J., Damme, P. V., Gray, E., et al. (2016) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2016.1167913 · Cited by 108

Errors within the total laboratory testing process, from test selection to medical decision-making – A review of causes, consequences, surveillance and solutions

Mrazek, C., Keppel, M. H., Cadamuro, J., Haschke‐Becher, E., Oberkofler, H., Felder, T. K., & Lippi, G. (2020) · Biochemia Medica · doi:10.11613/bm.2020.020502 · Cited by 135

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers

Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 100

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease

Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93

Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus

Čarná, M., Onyango, I. G., Katina, S., Holub, D., Novotný, J., Nezvedová, M., Jha, D., Nedelská, Z., Lacovich, V., Vyvere, T. V., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12970 · Cited by 101

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret‐Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

Vos, S. J. B., Visser, P. J., Verhey, F. R. J., Aalten, P., Knol, D. L., Ramakers, I. H. G. B., Scheltens, P., Rikkert, M. G. M. O., Verbeek, M. M., & Teunissen, C. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100784 · Cited by 92

Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults

Laws, S. M., Gaskin, S., Woodfield, A., Srikanth, V. K., Bruce, D. G., Fraser, P. E., Porter, T., Newsholme, P., Wijesekara, N., Burnham, S. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09577-4 · Cited by 98

Toward sensitive immuno-based detection of tau protein by surface plasmon resonance coupled to carbon nanostructures as signal amplifiers

Lisi, S., Scarano, S., Fedeli, S., Pascale, E., Cicchi, S., Ravelet, C., Peyrin, É., & Minunni, M. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.078 · Cited by 81

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease

Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

Vanderstichele, H., Janelidze, S., Demeyer, L., Coart, E., Stoops, E., Herbst, V., Mauroo, K., Brix, B., & Hansson, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160286 · Cited by 80

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey‐Smith, S. R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00595-5 · Cited by 81

Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42

Mattsson, N., Zegers, I., Andréasson, U., Bjerke, M., Blankenstein, M. A., Bowser, R. P., Carrillo, M. C., Gobom, J., Heath, T., Jenkins, R. G., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.39 · Cited by 79

Alzheimer’s Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study

Li, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 75

Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Chaulet, C., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Pasquier, F., Touchon, J., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.06.006 · Cited by 75

Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers

Wang, J., Fan, D., Li, H.-Y., He, C.-Y., Shen, Y., Zeng, G., Chen, D., Yi, X., Ma, Y., Yu, J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00512-w · Cited by 78

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Hey, J. A., Kočiš, P., Hort, J., Abushakra, S. R., Power, A., Vyhnálek, M., Yu, Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 76

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

Dorey, A., Perret‐Liaudet, A., Tholance, Y., Fourier, A., & Quadrio, I. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00247 · Cited by 74

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Arslan, B., & Zetterberg, H. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0036 · Cited by 69

Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid

Bastard, N. L., Deyn, P. P. D., & Engelborghs, S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.236679 · Cited by 71

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations

Mollenhauer, B., Batrla, R., El‐Agnaf, O. M. A., Galasko, D. R., Lashuel, H. A., Merchant, K., Shaw, L. M., Selkoe, D. J., Umek, R. M., Vanderstichele, H., et al. (2017) · Movement Disorders · doi:10.1002/mds.27090 · Cited by 70

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease

Schmidt, F. M., Mergl, R., Stach, B., Jahn, I., Gertz, H., & Schönknecht, P. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.007 · Cited by 67

Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

Mo, J.-A., Lim, J., Sul, A.-R., Lee, M. Y., Youn, Y. C., & Kim, H.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116802 · Cited by 67

Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 68

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms – A critical review

Scarano, S., Lisi, S., Ravelet, C., Peyrin, É., & Minunni, M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.08.008 · Cited by 67

Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases

Chen‐Plotkin, A. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.031 · Cited by 62

Pre-analytical factors influencing the stability of cerebrospinal fluid proteins

Simonsen, A. H., Bahl, J. M. C., Danborg, P. B., Lindström, V., Larsen, S. O., GRUBB, A. O., Heegaard, N. H. H., & Waldemar, G. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.03.011 · Cited by 62

Alzheimer’s Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy

Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 62

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57

The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer’s Disease: Results of a Randomized Trial

Berger, M., Nadler, J. W., Friedman, A. H., McDonagh, D. L., Bennett, E. R., Cooter, M. L., Qi, W., Laskowitz, D. T., Ponnusamy, V., Newman, M. F., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151190 · Cited by 59

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease

de Leon, M. J., Pirraglia, E., Osorio, R. S., Glodzik, L., Saint-Louis, L. A., Kim, H.-J., Fortea, J., Fossati, S., LASKA, E. M., Siegel, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191240 · Cited by 55

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit

Naylor, M. D., Karlawish, J. H., Arnold, S. E., Khachaturian, A. S., Khachaturian, Z. S., Lee, V. M. ‐., Baumgart, M., Banerjee, S., Beck, C. K., Blennow, K., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.08.001 · Cited by 58

Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study

Porter, T., Burnham, S. C., Milicic, L., Savage, G. R., Maruff, P. T., Lim, Y. Y., Li, Q.-X., Ames, D. J., Masters, C. L., Rainey‐Smith, S. R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180713 · Cited by 59

Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic

Sheardová, K., Vyhnálek, M., Nedelská, Z., Laczó, J., Andel, R., Marciniak, R., Cerman, J., Lerch, O., & Hort, J. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030379 · Cited by 58

A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease

Alegret, M., Muñoz, N., Roberto, N., Rentz, D. M., Valero, S., Gil, S., Marquié, M., Hernández, I., Riveros, C., Sanabria, Á., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00594-6 · Cited by 62

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Bjerke, M., Andréasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., Umek, R. M., Vanmechelen, E., Vanderstichele, H., Stoops, E., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0733 · Cited by 56

Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia

Bastard, N. L., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J., & Engelborghs, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121246 · Cited by 55

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Hanes, J., Kováč, A., Kvartsberg, H., Kontseková, E., Fialová, Ľ., Katina, S., Kováčech, B., Stevens, E., Hort, J., Vyhnálek, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010814 · Cited by 57

Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies

Slaets, S., Bastard, N. L., Theuns, J., Sleegers, K., Verstraeten, A., Leenheir, E. D., Luyckx, J., Martin, J., Broeckhoven, C. V., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122176 · Cited by 54

A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward

Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 56

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M. A., Lobanov, V. S., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04308.x · Cited by 52

A guide for measurement of circulating metabolic hormones in rodents: Pitfalls during the pre-analytical phase

Bielohuby, M., Popp, S., & Bidlingmaier, M. (2012) · Molecular Metabolism · doi:10.1016/j.molmet.2012.07.004 · Cited by 52

Oxidative Stress and Its Clinical Applications in Dementia

Mao, P. (2012) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/319898 · Cited by 56

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers

Leitão, M. J., Baldeiras, I., Herukka, S., Pikkarainen, M., Leinonen, V., Simonsen, A. H., Perret‐Liaudet, A., Fourier, A., Quadrio, I., Veiga, P. M., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00153 · Cited by 51

A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium

Somers, C., Struyfs, H., Goossens, J., Niemantsverdriet, E., Luyckx, J., Roeck, N. D., Roeck, E. E. D., Vil, B. B. D., Cras, P. P., Martin, J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151097 · Cited by 50

Cerebrospinal fluid tau proteins in status epilepticus.

Monti, G., Tondelli, M., Giovannini, G., Bedin, R., Nichelli, P. F., Trenti, T., Meletti, S., & Chiari, A. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.04.030 · Cited by 46

The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers

Soares, H. D., Ga̧sior, M., Toyn, J. H., Wang, J.-S., Hong, Q., Berisha, F., Furlong, M. T., Raybon, J. J., Lentz, K. A., Sweeney, F., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232256 · Cited by 48

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48

Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting

Gervaise-Henry, C., Watfa, G., Albuisson, É., Kolodziej, A., Dousset, B., Olivier, J. L., Jonveaux, T., & Malaplate, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160865 · Cited by 46

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Sasso, B. L., Iacolino, G., Giglio, R. V., Lupo, F., Alongi, P., Bivona, G., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1740939 · Cited by 46

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19

of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

(2016)

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret‐Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94